Evidence map›Paper›PMID 39043900›Full record

ArticleScientific reports2024

A non-toxic equinatoxin-II reveals the dynamics and distribution of sphingomyelin in the cytosolic leaflet of the plasma membrane.

Toshiki Mori, Takahiro Niki, Yasunori Uchida, Kojiro Mukai, Yoshihiko Kuchitsu, Takuma Kishimoto, Shota Sakai, Asami Makino, Toshihide Kobayashi, Hiroyuki Arai and 3 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Toshiki Mori *United Graduate School of Agricultural Science, Gifu University, Gifu, Japan.
Takahiro Niki *Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.
Yasunori Uchida *Laboratory of Organelle Pathophysiology, Department of Integrative Life Sciences, Graduate School of Life Sciences, Tohoku University, Sendai, Japan.
Kojiro MukaiLaboratory of Organelle Pathophysiology, Department of Integrative Life Sciences, Graduate School of Life Sciences, Tohoku University, Sendai, Japan.
Yoshihiko KuchitsuLaboratory of Organelle Pathophysiology, Department of Integrative Life Sciences, Graduate School of Life Sciences, Tohoku University, Sendai, Japan.
Takuma KishimotoDivision of Molecular Interaction, Institute for Genetic Medicine, Hokkaido University Graduate School of Life Science, Sapporo, Hokkaido, Japan.
Shota SakaiDepartment of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Tokyo, Japan.
Asami MakinoLipid Biology Laboratory, RIKEN, Wako, Saitama, Japan.
Toshihide KobayashiFaculté de Pharmacie, Université de Strasbourg, Illkirch, France.
Hiroyuki AraiDepartment of Health Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.
Yasunari YokotaDepartment of EECE, Faculty of Engineering, Gifu University, Gifu, Japan.
Tomohiko TaguchiLaboratory of Organelle Pathophysiology, Department of Integrative Life Sciences, Graduate School of Life Sciences, Tohoku University, Sendai, Japan. tomohiko.taguchi.b8@tohoku.ac.jp.
Kenichi G N SuzukiUnited Graduate School of Agricultural Science, Gifu University, Gifu, Japan. suzuki.kenichi.b7@f.gifu-u.ac.jp.

Funding

Japan Agency for Medical Research and Development 17939604Japan Science and Technology Agency JPMJCR18H2Japan Science and Technology Agency JPMJCR21E4Japan Science and Technology Agency JPMJSP2125Japan Society for the Promotion of Science JP19H00974Japan Society for the Promotion of Science JP20H05307Japan Society for the Promotion of Science JP21H02424Japan Society for the Promotion of Science JP21K06153Japan Society for the Promotion of Science JP22K11920
6 · The paper itself

Abstract

Sphingomyelin (SM) is a major sphingolipid in mammalian cells. SM is enriched in the extracellular leaflet of the plasma membrane (PM). Besides this localization, recent electron microscopic and biochemical studies suggest the presence of SM in the cytosolic leaflet of the PM. In the present study, we generated a non-toxic SM-binding variant (NT-EqtII) based on equinatoxin-II (EqtII) from the sea anemone Actinia equina, and examined the dynamics of SM in the cytosolic leaflet of living cell PMs. NT-EqtII with two point mutations (Leu26Ala and Pro81Ala) had essentially the same specificity and affinity to SM as wild-type EqtII. NT-EqtII expressed in the cytosol was recruited to the PM in various cell lines. Super-resolution microscopic observation revealed that NT-EqtII formed tiny domains that were significantly colocalized with cholesterol and N-terminal Lyn. Meanwhile, single molecule observation at high resolutions down to 1 ms revealed that all the examined lipid probes including NT-EqtII underwent apparent fast simple Brownian diffusion, exhibiting that SM and other lipids in the cytosolic leaflet rapidly moved in and out of domains. Thus, the novel SM-binding probe demonstrated the presence of the raft-like domain in the cytosolic leaflet of living cell PMs.

Indexed as

Cell MembraneCnidarian VenomsCytosolSphingomyelinsAnimalsCholesterolHumansSea AnemonesCholesterolCnidarian VenomsequinatoxinSphingomyelinsInner leafletNontoxic equinatoxin-II variantRaftsSingle molecule imagingSphingomyelinSuper-resolution microscopy

Identifiers

PMID39043900
PMCPMC11266560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.